Lacktman, Wein Quoted in mHealthIntelligence About OIG’s Approval of Free SmartPhone Giveaway for Medication Adherence Tracking
05 February 2019
mHealthIntelligence
Partner Nate Lacktman and Of Counsel Emily Wein were quoted in the mHealthIntelligence article, “OIG Oks Free Phones in mHealth Project Targeting Medication Adherence,” about the Office of the Inspector General decision to approve a digital health care company’s plan to loan free smartphones to patients enrolled in a project tracking medication adherence. The OIG last month ruled in favor of the digital health company’s plans which gives phones to patients enrolled in a digital therapeutic program in which they track medication adherence through an ingestible sensor and corresponding mobile health platform. This is the sixth time that the OIG has approved a projects like this.
Lacktman and Wein said the OIG ruled that the program did not violate anti-kickback laws for numerous reasons and also noted that the OIG’s ruling is specific to the case, but it points to support by the federal government for programs that improve access to care and health outcomes.
“OIG included its traditional disclaimer that the advisory opinion can only be relied upon by the specific company that requested it, and the opinion would be null if any material facts were not disclosed,” they wrote. “Companies offering similar digital health therapeutics or remote patient monitoring programs should closely review the opinion because it offers insight into the government’s view on how technology can promote access to care. Companies evaluating or developing similar programs offering free or discounted technology should carefully consider the safeguards enumerated in OIG’s analysis prior to launch.”
Lacktman and Wein said the OIG ruled that the program did not violate anti-kickback laws for numerous reasons and also noted that the OIG’s ruling is specific to the case, but it points to support by the federal government for programs that improve access to care and health outcomes.
“OIG included its traditional disclaimer that the advisory opinion can only be relied upon by the specific company that requested it, and the opinion would be null if any material facts were not disclosed,” they wrote. “Companies offering similar digital health therapeutics or remote patient monitoring programs should closely review the opinion because it offers insight into the government’s view on how technology can promote access to care. Companies evaluating or developing similar programs offering free or discounted technology should carefully consider the safeguards enumerated in OIG’s analysis prior to launch.”
People
Related News
06 February 2025
In the News
Vanessa Miller Assesses Panama Canal Discourse
Foley & Lardner LLP partner Vanessa Miller commented in SupplyChainBrain article, "The Fight for Control of the Panama Canal," lending important context to the recent headlines over the important waterway.
06 February 2025
In the News
Gregory Husisian Weighs in on Suspension of De Minimis Trade Exemption
Foley & Lardner LLP partner Gregory Husisian offered context on President Trump's recent trade actions on China in The Wall Street Journal article, "Why Trump Is Closing a Trade Exemption for China."
04 February 2025
In the News
Andrew Wronski on Tariff Fluidity – 'Keep on top of the issues'
Foley & Lardner LLP partner Andrew Wronski assessed the evolving shift in U.S. trade policy in the Milwaukee Business Journal article, "Trump tariffs won't disappear — so how should Wisconsin businesses prepare?"